Details of the Drug Combinations

General Information of This Drug (ID: DMQNWRD)

• Drug Name: Oxaliplatin (DMQNWRD)
• Synonyms: Eloxatin (TN); Medac (TN); Oxaliplatin (TN); Oxaliplatin (JAN/USAN/INN)

Indication

Adenocarcinoma; ICD 11: 2D40; Status: Approved [1]; Appendiceal neoplasm; ICD 11: N.A.; Status: Approved [1]; Cholangiocarcinoma; ICD 11: 2C12.10; Status: Approved [1]; Colon adenocarcinoma; ICD 11: N.A.; Status: Approved [1]; Colorectal cancer; ICD 11: 2B91.Z; Status: Approved [2]; Colorectal carcinoma; ICD 11: N.A.; Status: Approved [1]; Endocrine gland neoplasm; ICD 11: N.A.; Status: Approved [1]; Gallbladder carcinoma; ICD 11: N.A.; Status: Approved [1]; Metastasis from malignant tumor of colon; ICD 11: N.A.; Status: Approved [1]; Nasopharyngeal carcinoma; ICD 11: 2B6B; Status: Approved [1]; Peritoneal neoplasm; ICD 11: N.A.; Status: Approved [1]; Rectal adenocarcinoma; ICD 11: 2B92; Status: Approved [1]; Rectal neoplasm; ICD 11: N.A.; Status: Approved [1]; Rectum mucinous adenocarcinoma; ICD 11: N.A.; Status: Approved [1]; Colon cancer; ICD 11: 2B90.Z; Status: Investigative [1]; Gastric cancer; ICD 11: 2B72; Status: Investigative [1]

• Therapeutic Class: Anticancer Agents
• Drug Type: Small molecular drug

List of Combinatorial Drugs (CBD) Containing This Drug

62 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
ABT-888 + Oxaliplatin	DCEE9HL	ABT-888	Adenocarcinoma of the Pancreas	[3]
Bortezomib + Oxaliplatin	DCTXCEE	Bortezomib	Unspecified Adult Solid Tumor, Protocol Specific	[4]
Buparlisib + Oxaliplatin	DCWF9PL	Buparlisib	Advanced Solid Tumors	[5]
Cyclophosphamide + Oxaliplatin	DCIJBVF	Cyclophosphamide	Pancreatic Cancer	[6]
Docetaxel + Oxaliplatin	DCXQDVZ	Docetaxel	Esophagus Cancer	[7]
Docetaxel + Oxaliplatin	DCJLKL8	Docetaxel	Esophagus Cancer	[7]
Docetaxel + Oxaliplatin	DCXFBXW	Docetaxel	Esophageal Cancer	[8]
Docetaxel + Oxaliplatin	DCY0HZW	Docetaxel	Adenocarcinoma of the Gastroesophageal Junction	[9]
E7850 + Oxaliplatin	DCSKVK5	E7850	Liver Cancer	[10]
Epirubicin + Oxaliplatin	DC7H2DD	Epirubicin	Esophageal Cancer	[11]
Etoposide + Oxaliplatin	DC82FCV	Etoposide	Angioimmunoblastic T-cell Lymphoma	[12]
Gemcitabine + Oxaliplatin	DCCKCN9	Gemcitabine	Cancer of the Head and Neck	[13]
Gemcitabine + Oxaliplatin	DCMP46P	Gemcitabine	Lung Cancer	[14]
Gemcitabine + Oxaliplatin	DCI5L9F	Gemcitabine	Advanced Incurable Solid Malignancy	[15]
Gemcitabine + Oxaliplatin	DCWSX36	Gemcitabine	Advanced Gastrointestinal Malignancies	[16]
Irinotecan + Oxaliplatin	DCI5H5R	Irinotecan	Colorectal Cancer	[17]
Irinotecan + Oxaliplatin	DCIA2YB	Irinotecan	Unspecified Adult Solid Tumor, Protocol Specific	[18]
Lapatinib + Oxaliplatin	DC59A3V	Lapatinib	Neoplasms, Colorectal	[19]
Momelotinib + Oxaliplatin	DCB58IY	Momelotinib	Relapsed/Refractory Metastatic Pancreatic Ductal Adenocarcinoma	[20]
Napabucasin + Oxaliplatin	DCX2CN8	Napabucasin	Advanced Gastrointestinal Cancer	[21]
Oxaliplatin + Capecitabine	DCA8J4B	Capecitabine	Esophageal Cancer	[22]
Oxaliplatin + Capecitabine	DCBV3H2	Capecitabine	Colorectal Cancer	[23]
Oxaliplatin + Cediranib	DCIEZJJ	Cediranib	Metastatic Colorectal Cancer	[24]
Oxaliplatin + Raltitrexed	DCKEY5C	Raltitrexed	Colorectal Cancer	[25]
Oxaliplatin + Aflibercept	DCUA8H4	Aflibercept	Rectal Cancer	[26]
Oxaliplatin + Azacitidine	DCUEDWU	Azacitidine	Adult Solid Neoplasm	[27]
Oxaliplatin + Azacitidine	DC01CHR	Azacitidine	Colorectal Cancer	[28]
Oxaliplatin + Aflibercept	DCSKBNL	Aflibercept	Colorectal Cancer Metastatic	[29]
Paclitaxel + Oxaliplatin	DCUC9D5	Paclitaxel	Cervical Adenocarcinoma	[30]
Pemetrexed + Oxaliplatin	DCHGZZ8	Pemetrexed	Lung Cancer	[31]
Pemetrexed + Oxaliplatin	DCVMNXK	Pemetrexed	Lymphoma	[32]
Pralatrexate + Oxaliplatin	DCSDF09	Pralatrexate	Adenocarcinoma of the Gastroesophageal Junction	[33]
Regorafenib + Oxaliplatin	DC2UKR6	Regorafenib	Metastatic Colorectal Cancer	[34]
Regorafenib + Oxaliplatin	DC3TQFP	Regorafenib	Digestive Cancer	[35]
Tolcapone + Oxaliplatin	DCMZ702	Tolcapone	Neuroblastoma	[36]
Al3818 + Oxaliplatin	DCPJCJW	Al3818	Colorectal Cancer	[37]
Celecoxib + Oxaliplatin	DCL7TZ8	Celecoxib	Gastric Carcinoma	[38]
Docetaxel + Oxaliplatin	DCU1KY6	Docetaxel	Gastric Cancer	[39]
Docetaxel + Oxaliplatin	DCZA6J2	Docetaxel	Gastric Cancer	[40]
Epirubicin + Oxaliplatin	DC3EN7P	Epirubicin	Gastric Cancer	[41]
Epirubicin + Oxaliplatin	DC7PRHQ	Epirubicin	Esophageal Neoplasms	[42]
Epirubicin + Oxaliplatin	DCDNBR7	Epirubicin	CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction	[43]
Epirubicin + Oxaliplatin	DCRNVB3	Epirubicin	Gastro Oesophageal Cancer	[44]
Gemcitabine + Oxaliplatin	DCAX0X4	Gemcitabine	Pancreatic Cancer	[45]
Irinotecan + Oxaliplatin	DC1XR8L	Irinotecan	Small Intestine Adenocarcinoma	[46]
Irinotecan + Oxaliplatin	DC6ALSO	Irinotecan	Pancreatic Adenocarcinoma	[47]
Irinotecan + Oxaliplatin	DCX3992	Irinotecan	Adenocarcinoma of the Gastroesophageal Junction	[48]
Irinotecan + Oxaliplatin	DCZ66Q6	Irinotecan	Metastatic Colorectal Cancer	[49]
Oxaliplatin + Oxaliplatin	DC0QPQ3	Oxaliplatin	Cancer	[50]
Oxaliplatin + Capecitabine	DCCEH20	Capecitabine	Gastric Cancer	[51]
Oxaliplatin + Oxaliplatin	DCJQWDF	Oxaliplatin	Gastric Cancer	[39]
Pemetrexed + Oxaliplatin	DCOJZ0H	Pemetrexed	Esophagogastric Cancer	[52]
Rivoceranib + Oxaliplatin	DCCD4F9	Rivoceranib	Gastroesophageal Junction Adenocarcinoma	[53]
Rivoceranib + Oxaliplatin	DCYPGPQ	Rivoceranib	Gastric Cancer	[54]
Dexamethasone + Oxaliplatin	DCK4H0O	Dexamethasone	Metastatic Colorectal Cancer	[55]
Epirubicin + Oxaliplatin	DCEWIV9	Epirubicin	Gastric Cancer	[56]
Floxuridine + Oxaliplatin	DCZZPAN	Floxuridine	Colorectal Cancer	[57]
Gemcitabine + Oxaliplatin	DCOQO10	Gemcitabine	Diffuse Large B-Cell Lymphoma	[58]
Lapatinib + Oxaliplatin	DCY85TZ	Lapatinib	Neoplasms, Gastrointestinal Tract	[59]
Oxaliplatin + Capecitabine	DC68Z3S	Capecitabine	Rectal Neoplasms Malignant	[60]
Oxaliplatin + Magnesium Sulfate	DCGYPD4	Magnesium Sulfate	Chemotherapeutic Agent Toxicity	[61]
Tegafur + Oxaliplatin	DCSNGT4	Tegafur	Gastric Cancer	[62]

References

• [1] Oxaliplatin FDA Label
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7433).
• [3] ClinicalTrials.gov (NCT01233505) Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors
• [4] ClinicalTrials.gov (NCT00066625) Oxaliplatin and Bortezomib in Treating Patients With Advanced Cancer
• [5] ClinicalTrials.gov (NCT01571024) BKM120 + mFOLFOX6 in Advanced Solid Tumors With Expansion Cohort Pancreatic Cancer
• [6] ClinicalTrials.gov (NCT01595321) Pancreatic Tumor Cell Vaccine (GVAX), Low Dose Cyclophosphamide, Fractionated Stereotactic Body Radiation Therapy (SBRT), and FOLFIRINOX Chemotherapy in Patients With Resected Adenocarcinoma of the Pancreas
• [7] ClinicalTrials.gov (NCT00193128) Preoperative Therapy With Oxaliplatin/Docetaxel/Capecitabine and Radiation in Resectable Esophagus Cancer
• [8] ClinicalTrials.gov (NCT00217581) Bevacizumab, Oxaliplatin, and Docetaxel in Treating Patients With Locally Advanced Unresectable or Metastatic Stomach or Gastroesophageal Junction Cancer
• [9] ClinicalTrials.gov (NCT00732745) Vandetanib, Oxaliplatin, and Docetaxel in Advanced Cancer of the Esophagus or Gastroesophageal Junction
• [10] ClinicalTrials.gov (NCT00374660) Study of Irofulven in Combination With Oxaliplatin in Patients With Advanced Solid Tumors
• [11] ClinicalTrials.gov (NCT01386346) Epigenetic Priming Using Azacitidine With Neoadjuvant Chemotherapy for Resectable Esophageal Cancer
• [12] ClinicalTrials.gov (NCT00101205) Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
• [13] ClinicalTrials.gov (NCT00256295) Weekly Oxaliplatin and Gemcitabine for Recurrent or Metastatic Head and Neck Cancer
• [14] ClinicalTrials.gov (NCT00452881) Adjuvant Gemcitabine Plus Oxaliplatin Versus Gemcitabine Plus Cisplatin for Completely Resected Stage IB/II/IIIA NSCLC
• [15] ClinicalTrials.gov (NCT00660725) Study of GemOx and Vandetanib in Advanced Solid Malignancy
• [16] ClinicalTrials.gov (NCT00660426) Study Of Advanced Gastrointestinal Malignancies And Other Solid Tumors
• [17] ClinicalTrials.gov (NCT00003594) Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer
• [18] ClinicalTrials.gov (NCT00074321) Irinotecan, Oxaliplatin, and Capecitabine in Treating Patients With Unresectable Solid Tumors
• [19] ClinicalTrials.gov (NCT00536809) Phase I/II Study of Lapatinib in Combination With Oxaliplatin and Capecitabine in Subjects With Advanced Colorectal Cancer
• [20] ClinicalTrials.gov (NCT02244489) Momelotinib Combined With Capecitabine and Oxaliplatin in Adults With Relapsed/Refractory Metastatic Pancreatic Ductal Adenocarcinoma
• [21] ClinicalTrials.gov (NCT02024607) A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer
• [22] ClinicalTrials.gov (NCT00040859) Oxaliplatin and Capecitabine in Treating Patients With Advanced Esophageal Cancer or Stomach Cancer
• [23] ClinicalTrials.gov (NCT00058474) Radiation Therapy and Either Capecitabine or Fluorouracil With or Without Oxaliplatin Before Surgery in Treating Patients With Resectable Rectal Cancer
• [24] ClinicalTrials.gov (NCT00494221) A Phase I/II Study of Cediranib (AZD2171) in Japanese Metastatic Colorectal Cancer Patients in Combination With FOLFOX
• [25] ClinicalTrials.gov (NCT01348412) Hepatic Arterial Chemotherapy With Raltitrexed and Oxaliplatin Versus Standard Chemotherapy in Unresectable Liver Metastases From Colorectal Cancer After Conventional Chemotherapy Failure
• [26] ClinicalTrials.gov (NCT01749956) 5-FU, Aflibercept, and Radiation (RT) for Preoperative and Postoperative Patients With Stage II/III Rectal Cancer
• [27] ClinicalTrials.gov (NCT01039155) Azacitidine and Oxaliplatin In Treating Patients With Advanced Cancers Relapsed or Refractory to Any Platinum Therapy
• [28] ClinicalTrials.gov (NCT01193517) Azacitidine and CAPOX in Metastatic Colorectal Cancer
• [29] ClinicalTrials.gov (NCT01955629) Study of Aflibercept as Maintenance Therapy Following Induction With Aflibercept in Combination With XELOX, as First-Line Treatment for Metastatic Colorectal Cancer Patient
• [30] ClinicalTrials.gov (NCT00057863) Oxaliplatin and Paclitaxel in Treating Patients With Locally Recurrent or Metastatic Cervical Cancer
• [31] ClinicalTrials.gov (NCT00612677) Pemetrexed &Oxaliplatin in Patients w Recurrent NSCLCa After Failure to Platinum Based Adjuvant Chem
• [32] ClinicalTrials.gov (NCT00470405) Pemetrexed and Oxaliplatin in Treating Patients With Metastatic Solid Tumors or Lymphoma
• [33] ClinicalTrials.gov (NCT01178944) Pralatrexate and Oxaliplatin in Treating Patients With Unresectable or Metastatic Esophageal, Stomach, or Gastroesophageal Junction Cancer
• [34] ClinicalTrials.gov (NCT04008511) Regorafenib and XELOX as 2nd Line Treatment in Metastatic Colorectal Cancer
• [35] ClinicalTrials.gov (NCT02386397) Activity of Regorafenib in Combination With Chemotherapy in Patients With Advanced Biliary Tract Cancer
• [36] ClinicalTrials.gov (NCT02630043) Trial of Tolcapone With Oxaliplatin for Neuroblastoma
• [37] ClinicalTrials.gov (NCT04080843) Anlotinib Hydrochloride Capsules Combined With CAPEOX in RAS and BRAF Wild-type mCRC Patients
• [38] ClinicalTrials.gov (NCT00256321) Celecoxib/Oxaliplatin/Capecitabine for Gastric/Gastroesophageal Junction Carcinoma
• [39] ClinicalTrials.gov (NCT02725424) Optimizing the Strategy for Preoperative Chemotherapy in Locally Advanced Gastric/Gastroesophageal Cancer
• [40] ClinicalTrials.gov (NCT02931890) Multicentric Randomised Trial for Resectable Gastric Cancer
• [41] ClinicalTrials.gov (NCT00454636) A Study of Xeloda (Capecitabine) in Combination With Chemotherapy in Patients With Advanced and/or Metastatic Gastric Cancer.
• [42] ClinicalTrials.gov (NCT02177552) Study Assessing the Effects of Chemotherapy in Advanced Esophagogastric Adenocarcinoma
• [43] ClinicalTrials.gov (NCT01630083) Efficacy and Safety of IMAB362 in Combination With the EOX Regimen for CLDN18.2-positive Gastric Cancer
• [44] ClinicalTrials.gov (NCT01710592) A Phase II Trial of Epirubicin, Oxaliplatin and Capecitabine (EOX) Versus Docetaxel and Oxaliplatin (ElTax) in the Treatment of Advanced Gastro-oesophageal Cancer
• [45] ClinicalTrials.gov (NCT00408564) Cetuximab, Gemcitabine, and Oxaliplatin Followed By Surgery or External-Beam Radiation Therapy and Capecitabine in Treating Patients With Locally Advanced, Nonmetastatic Pancreatic Cancer That Cannot Be Removed By Surgery
• [46] ClinicalTrials.gov (NCT00433550) Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Cancer
• [47] ClinicalTrials.gov (NCT01558869) Xeloxiri as First-line Treatment in Patients With Advanced Unresectable Pancreatic Adenocarcinoma
• [48] ClinicalTrials.gov (NCT00084617) Phase II Study of Oxaliplatin, Irinotecan, and Capecitabine in Advanced Gastric/Gastroesophageal Junction Carcinoma
• [49] ClinicalTrials.gov (NCT04097444) CAPOXIRI+Bevacizumab vs. FOLFOXIRI+Bevacizumab for mCRC
• [50] ClinicalTrials.gov (NCT00177307) Safety and Efficacy Study Using Bevacizumab, Capecitabine and Oxaliplatin for Colorectal Cancer
• [51] ClinicalTrials.gov (NCT03817411) Telatinib in Combination With Capecitabine/ Oxaliplatin in 1st Line Gastric or GEJ Cancer
• [52] ClinicalTrials.gov (NCT02296671) Personalized Therapy for Esophagogastric Cancer Using Thymidylate Synthase Genetic Markers
• [53] ClinicalTrials.gov (NCT03349866) A Prospective Study of Apatinib Plus Concurrent Neoadjuvant Chemoradiotherapy for Siewert II III of Locally Advanced HER-2 Negative Adenocarcinoma at Gastroesophageal Junction
• [54] ClinicalTrials.gov (NCT03472365) A Study of SHR-1210 in Combination With Capecitabine + Oxaliplatin or Apatinib in Treatment of Advanced Gastric Cancer
• [55] ClinicalTrials.gov (NCT02102789) A Study of Systemic Chemotherapy With/Without HAI in Patients With Initially Unresectable Colorectal Liver Metastasis
• [56] ClinicalTrials.gov (NCT02395640) The Comparison of XELOX and EOX in the First-line Treatment of Advanced Gastric Cancer
• [57] ClinicalTrials.gov (NCT00268463) Oxaliplatin and Capecitabine With or Without an Hepatic Arterial Infusion With Floxuridine in Treating Patients Who Are Undergoing Surgery and/or Ablation for Liver Metastases Due to Colorectal Cancer
• [58] ClinicalTrials.gov (NCT02951156) Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)
• [59] ClinicalTrials.gov (NCT00680901) LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib
• [60] ClinicalTrials.gov (NCT04103697) Neoadjuvant Chemotherapy in Patients With Intermediate Risk Upper and Mid Rectal Cancer
• [61] ClinicalTrials.gov (NCT01099449) Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity in Patients With Colon Cancer or Rectal Cancer Receiving Oxaliplatin-Based Combination Chemotherapy
• [62] ClinicalTrials.gov (NCT05914610) Envollizumab Combined With Fruquintinib and SOX Versus SOX for Conversion Therapy in Advanced Gastric Cancer